Cardurion Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

2024-01-05

BURLINGTON, Mass.--(BUSINESS WIRE)-- Cardurion Pharmaceuticals, Inc. (“Cardurion”) a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced it will present during the private company track at the 42nd Annual J.P. Morgan Healthcare Conference. Peter Lawrence, Chief Executive Officer of Cardurion, will provide a corporate overview, including recent clinical development progress and upcoming milestones. The presentation will occur on Monday January 8, 2024 at 4:00 PM PST at The Westin St. Francis Hotel in San Francisco, California. About Cardurion Pharmaceuticals Cardurion is a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases. Cardurion was founded by physician-scientists with world-class expertise in cardiovascular signaling pathways, and a shared passion to find and develop a pipeline of novel treatment options to improve the lives of patients. Cardurion has two groundbreaking clinical programs in development, a PDE9 program targeting heart failure and the first ever CaMKII inhibitor CaMKII inhibitor in clinical development targeting multiple cardiovascular indications. Cardurion Pharmaceuticals has facilities in Burlington, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at .

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构